HRP20030348A2 - Compositions and methods for lowering plasma lipoprotein (a) and risk factors of cardiovascular diseases - Google Patents

Compositions and methods for lowering plasma lipoprotein (a) and risk factors of cardiovascular diseases Download PDF

Info

Publication number
HRP20030348A2
HRP20030348A2 HR20030348A HRP20030348A HRP20030348A2 HR P20030348 A2 HRP20030348 A2 HR P20030348A2 HR 20030348 A HR20030348 A HR 20030348A HR P20030348 A HRP20030348 A HR P20030348A HR P20030348 A2 HRP20030348 A2 HR P20030348A2
Authority
HR
Croatia
Prior art keywords
composition
lipoprotein
plasma
glycinate
biochemical substances
Prior art date
Application number
HR20030348A
Other languages
English (en)
Croatian (hr)
Inventor
Rath Matthias
Original Assignee
Rath Matthias
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rath Matthias filed Critical Rath Matthias
Publication of HRP20030348A2 publication Critical patent/HRP20030348A2/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
HR20030348A 2000-10-03 2001-10-03 Compositions and methods for lowering plasma lipoprotein (a) and risk factors of cardiovascular diseases HRP20030348A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23718600P 2000-10-03 2000-10-03
PCT/US2001/031203 WO2002028379A2 (en) 2000-10-03 2001-10-03 Compositions and methods for lowering plasma lipoprotein(a) and risk factors of cardiovascular diseases

Publications (1)

Publication Number Publication Date
HRP20030348A2 true HRP20030348A2 (en) 2005-06-30

Family

ID=22892673

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20030348A HRP20030348A2 (en) 2000-10-03 2001-10-03 Compositions and methods for lowering plasma lipoprotein (a) and risk factors of cardiovascular diseases

Country Status (24)

Country Link
US (2) US6693129B2 (cs)
EP (1) EP1324753A2 (cs)
JP (1) JP2004525080A (cs)
KR (1) KR20030070003A (cs)
CN (1) CN100421659C (cs)
AU (2) AU1145202A (cs)
BR (1) BR0114526A (cs)
CA (1) CA2424880A1 (cs)
CZ (1) CZ20031167A3 (cs)
EE (1) EE200300136A (cs)
HR (1) HRP20030348A2 (cs)
HU (1) HUP0303040A3 (cs)
IL (2) IL155238A0 (cs)
MX (1) MXPA03002964A (cs)
NO (1) NO20031510L (cs)
NZ (2) NZ525390A (cs)
PL (1) PL212479B1 (cs)
RO (1) RO120567B1 (cs)
RU (1) RU2289406C2 (cs)
SK (1) SK5252003A3 (cs)
TR (1) TR200300594T2 (cs)
UA (1) UA77660C2 (cs)
WO (1) WO2002028379A2 (cs)
ZA (1) ZA200302772B (cs)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002221131A1 (en) * 2000-12-14 2002-06-24 Sankyo Company Limited Blood lipid ameliorant composition
PT1397148E (pt) * 2001-02-27 2006-11-30 Nutrition 21 Inc Tratamento da dislipidemia com crómio/biotina
US20030054978A1 (en) * 2001-08-31 2003-03-20 Babish John G. Arginine compositions for coordinate modification of multiple cardiovascular risk factors
US20040097467A1 (en) * 2002-08-22 2004-05-20 Vijaya Juturu Arginine silicate inositol complex and use thereof
US7635469B2 (en) * 2002-08-28 2009-12-22 Premier Micronutrient Corporation Micronutrient formulations for hearing health
US20080020035A1 (en) * 2002-08-28 2008-01-24 Kedar Prasad Micronutrient formulations and related methods of manufacture
US20080145424A1 (en) * 2002-10-24 2008-06-19 Enos Phramaceuticals, Inc. Sustained release L-arginine formulations and methods of manufacture and use
KR20050083827A (ko) * 2002-10-24 2005-08-26 이노스 파마슈티칼스, 인코포레이티드 서방성 ｌ-아르기닌 포뮬레이션 및 이의 제조방법 및 용도
US20050053673A1 (en) * 2003-09-05 2005-03-10 Shrirang Netke Composition and method for facilitating bone healing
CA2540202A1 (en) * 2003-09-29 2005-04-21 Enos Pharmaceuticals, Inc. Sustained release l-arginine formulations and methods of manufacture and use
US20050074443A1 (en) * 2003-10-03 2005-04-07 Treadwell Benjamin V. Methods of attenuating autoimmune disease and compositions useful therefor
JP2005187454A (ja) * 2003-12-05 2005-07-14 Sankyo Co Ltd ビタミンｅ含有ｌｄｌ低下剤及び／又は動脈硬化抑制剤組成物
JP2005225871A (ja) * 2004-01-16 2005-08-25 Sankyo Co Ltd 血中トリグリセライド又はホモシステインを低下させる医薬組成物
US20080032952A1 (en) * 2004-07-09 2008-02-07 Marjorie Zettler Combination Therapies Employing Nicotinic Acid Derivatives or Fibric Acid Derivatives
JP4896531B2 (ja) * 2005-01-25 2012-03-14 第一三共ヘルスケア株式会社 血中ＣｏＱ１０量を増加させる医薬組成物
US7628984B2 (en) * 2005-02-17 2009-12-08 Premier Micronutrient Corporation Micronutrient formulations for pulmonary and heart health
US7887852B2 (en) * 2005-06-03 2011-02-15 Soft Gel Technologies, Inc. Soft gel capsules containing polymethoxylated flavones and palm oil tocotrienols
US20070072910A1 (en) * 2005-09-29 2007-03-29 Smith Michael L Compositions and methods for lowering plasma concentrations of low density lipoproteins in humans
KR100592719B1 (ko) * 2005-10-05 2006-06-28 케이에스엠기술 주식회사 하천의 생태계 보호용 이물질 유입방지 시설
US20070292493A1 (en) * 2006-06-15 2007-12-20 Brierre Barbara T Pharmaceutical composition and method for the transdermal delivery of calcium
US20080207748A1 (en) * 2007-02-22 2008-08-28 Innovation Labs, Inc. Vitamin c preparation
EP3050568B1 (en) 2007-03-13 2020-12-02 JDS Therapeutics, LLC Methods and compositions for the sustained release of chromium
WO2008139314A1 (en) * 2007-05-11 2008-11-20 Horphag Research (Luxembourg) Holding Sa Compositions and methods for treating joint disorders
US7867524B2 (en) * 2007-10-05 2011-01-11 David Rowland Energizing formulation
RU2377007C1 (ru) * 2008-06-23 2009-12-27 Открытое Акционерное Общество "Инвестиционная Финансовая Группа "Гленик-М" Средство для лечения и профилактики онкологических заболеваний и способ применения этого средства (варианты)
RU2385722C1 (ru) * 2008-07-02 2010-04-10 Тимофей Георгиевич Кожока Фармацевтическая нейропротекторная, антиоксидантная, антигипоксантная, антиапоптотическая и мембранопротекторная композиция и способ лечения
US20110091618A1 (en) * 2009-10-16 2011-04-21 Frito-Lay North America, Inc. Method for preventing oxidation and off flavors in high carotenoid foods
RU2468791C2 (ru) * 2011-02-24 2012-12-10 Общество с ограниченной ответственностью "ДИНАМИК ДЕВЕЛОПМЕНТ ЛАБОРАТОРИЗ" Композиция, обладающая адаптогенным, общеукрепляющим и повышающим работоспособность действием
EA025844B1 (ru) * 2012-05-08 2017-02-28 Общество С Ограниченной Ответственностью "Лигур-М" Средство для коррекции гиперхолестеринемии
WO2015199537A1 (en) * 2014-06-24 2015-12-30 Dedraf Holding B.V. New mineral composition
US10499682B2 (en) 2014-08-25 2019-12-10 New Age Beverage Corporation Micronutrient formulation in electronic cigarettes
US11191735B2 (en) 2015-03-13 2021-12-07 Nutrition 21, Llc Arginine silicate for periodontal disease
US20170135969A1 (en) 2015-11-12 2017-05-18 Jds Therapeutics, Llc Topical arginine-silicate-inositol for wound healing
CA3014308A1 (en) 2016-02-11 2017-08-17 Nutrition 21, Llc Chromium containing compositions for improving health and fitness
CN106213522A (zh) * 2016-08-05 2016-12-14 郑家福 营养保健品
US11357250B2 (en) 2016-08-15 2022-06-14 Summit Innovation Labs LLC Treatment and prevention of diabetes and obesity
US11344575B2 (en) * 2016-08-15 2022-05-31 Summit Innovation Labs, LLC Vascular calcification prevention and treatment
GB2568849B (en) 2016-09-01 2022-08-10 Nutrition 21 Llc Magnesium biotinate compositions and methods of use
SE540582C2 (en) * 2016-12-22 2018-10-02 Scandibio Therapeutics Ab Substances for treatment of fatty liver-related conditions
EP3398601A1 (en) * 2017-05-02 2018-11-07 Salmon Pharma GmbH Nicotinamide for treating dyslipidemia
CN108033939B (zh) * 2017-12-26 2020-09-11 上海共晶医药科技有限公司 生育酚与脯氨酸的共结晶及其制备方法
CN109092262B (zh) * 2018-08-28 2019-07-05 广州达济医学科技有限公司 低密度脂蛋白吸附微球及制备方法和吸附材料
JP2022515314A (ja) 2018-11-02 2022-02-18 ニュートリション・２１，エルエルシー イノシトール安定化アルギニンケイ酸塩複合体及びイノシトールを含有するビデオゲームプレーヤーの認知機能を改善するための組成物
WO2020139698A1 (en) * 2018-12-26 2020-07-02 Colgate-Palmolive Company Specific co-aggregation inhibition by arginine
GB2613672A (en) 2019-12-16 2023-06-14 Nutrition 21 Llc Methods of production of aginine-silicate complexes
CN119522095A (zh) 2022-07-01 2025-02-25 N·V·努特里奇亚 用于神经退行性病变和神经创伤的营养组合物
IT202300020718A1 (it) * 2023-10-06 2025-04-06 Promin Prod Di Medicina Integrata S R L Composizione a base di inositolo e proantocianidine oligomeriche

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1356370A (en) * 1972-03-06 1974-06-12 Howard A N Methods and formulations for the treatment of obesity
US4414238A (en) * 1981-12-24 1983-11-08 Cutter Laboratories, Inc. Liquid elemental diet
US4657866A (en) * 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4891220A (en) * 1988-07-14 1990-01-02 Immudyne, Inc. Method and composition for treating hyperlipidemia
US5268181A (en) 1989-04-13 1993-12-07 Upsher-Smith Laboratories, Inc. Method of using niacin to control nocturnal cholesterol synthesis
US6451341B1 (en) * 1990-02-05 2002-09-17 Thomas J. Slaga Time release formulation of vitamins, minerals and other beneficial supplements
US5278189A (en) * 1990-06-04 1994-01-11 Rath Matthias W Prevention and treatment of occlusive cardiovascular disease with ascorbate and substances that inhibit the binding of lipoprotein (A)
US5650418A (en) * 1990-06-04 1997-07-22 Therapy 2000 Therapeutic lysine salt composition and method of use
US5230996A (en) * 1990-06-04 1993-07-27 Therapy 2000 Use of ascorbate and tranexamic acid solution for organ and blood vessel treatment prior to transplantation
US5308627A (en) * 1990-08-07 1994-05-03 Umbdenstock Jr Anthony J Nutritional supplement for optimizing cellular health
JPH06501695A (ja) * 1990-10-01 1994-02-24 ブリガム・アンド・ウイメンズ・ホスピタル 主要血管事象を抑制するためのベータ−カロテン及びビタミンｅ療法
US5108767A (en) * 1991-06-10 1992-04-28 Abbott Laboratories Liquid nutritional product for persons receiving renal dialysis
GB2268871A (en) * 1992-07-04 1994-01-26 Bio Nutritional Health Service Composition for use as a food or food supplement
US5326569A (en) * 1992-12-23 1994-07-05 Abbott Laboratories Medical foods for the nutritional support of child/adult metabolic diseases
US5962517A (en) * 1997-01-31 1999-10-05 Murad; Howard Pharmaceutical compositions and methods for treating acne
US5922766A (en) * 1997-07-02 1999-07-13 Acosta; Phyllis J. B. Palatable elemental medical food
EP1068868A3 (en) * 1997-07-08 2001-01-31 Rath, Matthias, Dr. med. Synergistic compositions comprising ascorbate and lysine for states related to extracellular matrix degeneration
EP0891771A1 (en) * 1997-07-08 1999-01-20 Health Now, Inc. Compositions comprising lysine and ascorbate compounds for the treatment and prevention of cardiovascular diseases
US6048846A (en) * 1998-02-26 2000-04-11 Cochran; Timothy M. Compositions used in human treatment
US6299896B1 (en) * 2000-04-13 2001-10-09 Cooper Concepts, Inc. Multi-vitamin and mineral supplement
US6361800B1 (en) * 2000-04-13 2002-03-26 Cooper Concepts, Inc. Multi-vitamin and mineral supplement
EP1163904B1 (en) * 2000-06-16 2006-04-19 Rath, Matthias, Dr. med. Composition for the prevention of smooth muscle diseases comprising ascorbate, arginine and magnesium
DE60028376T2 (de) * 2000-10-09 2007-06-06 Rath, Matthias, Dr. Therapeutische Kombination des Ascorbats mit Lysin und Arginin für Verhinderung und Behandlung des Krebses
US6974833B2 (en) * 2001-01-16 2005-12-13 Matthias Rath Synergistic compositions comprising ascobate and lysine for states related to extra cellular matrix degeneration
UA76444C2 (en) * 2001-02-14 2006-08-15 Composition of biochemical compounds involved in bioenergy metabolism of cells and method of its use in prevention and therapy of diseases
US6686340B2 (en) * 2001-06-19 2004-02-03 Matthias Rath Composition and method for prevention and treatment of health conditions caused by constriction of smooth muscle cells

Also Published As

Publication number Publication date
PL365986A1 (en) 2005-01-24
JP2004525080A (ja) 2004-08-19
HUP0303040A3 (en) 2005-05-30
WO2002028379A2 (en) 2002-04-11
IL155238A0 (en) 2003-11-23
CN100421659C (zh) 2008-10-01
HUP0303040A2 (hu) 2003-12-29
ZA200302772B (en) 2004-10-18
MXPA03002964A (es) 2004-12-06
US20020094996A1 (en) 2002-07-18
CN1477959A (zh) 2004-02-25
BR0114526A (pt) 2005-04-26
WO2002028379A3 (en) 2003-02-27
NO20031510L (no) 2003-06-02
SK5252003A3 (en) 2004-01-08
US6693129B2 (en) 2004-02-17
US20040157895A1 (en) 2004-08-12
PL212479B1 (pl) 2012-10-31
UA77660C2 (en) 2007-01-15
CA2424880A1 (en) 2002-04-11
KR20030070003A (ko) 2003-08-27
NO20031510D0 (no) 2003-04-03
EE200300136A (et) 2003-08-15
AU2002211452B2 (en) 2005-10-27
TR200300594T2 (tr) 2004-10-21
EP1324753A2 (en) 2003-07-09
RU2289406C2 (ru) 2006-12-20
NZ525390A (en) 2006-04-28
US7244749B2 (en) 2007-07-17
NZ545806A (en) 2008-04-30
IL185384A (en) 2008-06-05
AU1145202A (en) 2002-04-15
CZ20031167A3 (cs) 2003-12-17
RO120567B1 (ro) 2006-04-28

Similar Documents

Publication Publication Date Title
HRP20030348A2 (en) Compositions and methods for lowering plasma lipoprotein (a) and risk factors of cardiovascular diseases
AU2002211452A1 (en) Compositions and methods for lowering plasma lipoprotein(a) and risk factors of cardiovascular diseases
US20170172954A1 (en) Treatment of NASH with Gemcabene
Hoffbrand Deferiprone therapy for transfusional iron overload
MXPA04012149A (es) El uso de cianopirrolidinas sustituidas y prepraraciones de combinacion que las contienen para tratar hiperlipidemia y enfermedades asociadas.
AU2018444285A1 (en) Compositions for reducing serum uric acid
AU2004290925B2 (en) Pharmaceutical compositions for the treatment of renal dysfunction, disease or disorder, in particular in diabetic patients
KR101765678B1 (ko) 당뇨병성 신장병증상의 예방 또는 치료제
SK15382001A3 (sk) Farmaceutický prostriedok obsahujúci amlodipín, spôsob liečenia a spôsob znižovania krvného tlaku
King et al. Pharmacokinetics and antipsychotic effect of remoxipride in chronic schizophrenic patients
TWI451866B (zh) 治療及預防患者因心肌缺血所引起的不適的醫藥組合物
KR20060066176A (ko) 데커신 및/또는 데커시놀 안젤레이트, 또는 데커신및/또는 데커시놀 안젤레이트를 유효성분으로 하는당귀추출물을 포함하는 신기능 치료제 조성물
MXPA99000074A (en) A method for treating liver diseases and similar indications with vasodilated agents
Foody High-Density Lipoprotein Cholesterol, Triglycerides, and Coronary Artery Disease: Clinical Evidence and Clinical Implications
McKenney et al. Use of response surface analysis to determine the dose of a reductase inhibitor and bile acid resin regimen for optimal LDL-cholesterol lowering
JPWO2003004036A1 (ja) 二次性副甲状腺機能亢進症の治療用医薬組成物および二次性副甲状腺機能亢進症治療に伴う心血管系合併症の治療薬
JP2002529408A (ja) アポトーシスを誘導することができる薬剤の調製のためのプロピオニルｌ−カルニチンの使用
HK1097762B (en) Pharmaceutical compositions for the treatment of renal dysfunction, disease or disorder, in particular in diabetic patients
JPS6314722A (ja) 高脂血症治療剤
AU2004280108A1 (en) Methods and means for modulating lipid metabolism

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20061023

Year of fee payment: 6

OBST Application withdrawn